{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["25(1)"],"submitter":["Singh N"],"pubmed_abstract":["<h4>Background</h4>Progesterone is known to maintain uterine quiescence as pregnancy advances. Recently, its efficacy in preventing preterm birth has been questioned prompting a search for an alternative treatment option. Cyclic AMP has been shown invitro to act in synergy with progesterone to maintain uterine quiescence.<h4>Methods</h4>We undertook an open label randomised feasibility study to test the hypothesis that the addition of aminophylline to the standard of care (SoC) is acceptable and can be tolerated in pregnant women at high risk of spontaneous preterm labour (sPTL). Women at high risk of sPTL, who met the inclusion criteria were invited to participate and randomised to receive the SoC (progesterone alone, n = 33) or treatment with the SoC and aminophylline (n = 37). The main "],"journal":["BMC pregnancy and childbirth"],"pagination":["357"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11948830"],"repository":["biostudies-literature"],"pubmed_title":["A randomised feasibility tolerability study of aminophylline for the prevention of preterm labour."],"pmcid":["PMC11948830"],"pubmed_authors":["Shah NM","Bourke M","Battersby C","Tribe RM","Johnson MR","Singh N","Sooranna G","Yulia A"],"additional_accession":[]},"is_claimable":false,"name":"A randomised feasibility tolerability study of aminophylline for the prevention of preterm labour.","description":"<h4>Background</h4>Progesterone is known to maintain uterine quiescence as pregnancy advances. Recently, its efficacy in preventing preterm birth has been questioned prompting a search for an alternative treatment option. Cyclic AMP has been shown invitro to act in synergy with progesterone to maintain uterine quiescence.<h4>Methods</h4>We undertook an open label randomised feasibility study to test the hypothesis that the addition of aminophylline to the standard of care (SoC) is acceptable and can be tolerated in pregnant women at high risk of spontaneous preterm labour (sPTL). Women at high risk of sPTL, who met the inclusion criteria were invited to participate and randomised to receive the SoC (progesterone alone, n = 33) or treatment with the SoC and aminophylline (n = 37). The main ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Mar","modification":"2026-06-02T20:38:21.489Z","creation":"2025-06-25T03:04:40.225Z"},"accession":"S-EPMC11948830","cross_references":{"pubmed":["40148792"],"doi":["10.1186/s12884-025-07488-1"]}}